- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 184 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 332 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
| 16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
| 16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha | ||
| 16.07. | OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.07. | OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain | 202 | GlobeNewswire (Europe) | After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating... ► Artikel lesen | |
| 16.07. | Positive Studiendaten zu Augenschmerzmittel beflügeln OKYO-Pharma-Aktie | 1 | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma stock surges after positive Phase 2 results for eye pain drug | 2 | Investing.com | ||
| 11.06. | Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | 409 | ACCESS Newswire | Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap... ► Artikel lesen | |
| 11.06. | OKYO Pharma to Present at the Bio International Convention | 310 | GlobeNewswire (Europe) | LONDON and NEW YORK, June 11, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
| 11.06. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 19.05. | OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit | 336 | GlobeNewswire (Europe) | LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.05. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 532,80 | -1,84 % | IDEXX beruft Tech-Expertin Karen Peacock in den Verwaltungsrat | ||
| ADAPTIMMUNE THERAPEUTICS | 0,162 | -0,61 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,250 | +3,45 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 4,224 | -2,00 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,050 | +0,88 % | Anavex presents oral blarcamesine data at Alzheimer Europe Conference | ||
| CELLAVISION | 16,280 | -0,85 % | CellaVision: CellaVision appoints Monica Jönsson as Interim CFO | Monica Jönsson has been appointed Interim Chief Financial Officer (CFO) and succeeds Magnus Blixt, who has left the company as previously communicated.Monica has extensive experience from leading positions... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 4,760 | -2,86 % | Precision BioSciences publishes research on ARCUS gene editing platform | ||
| ZYMEWORKS | 15,500 | -0,64 % | Zymeworks Inc.: Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer | VANCOUVER, British Columbia, Oct. 09, 2025(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... ► Artikel lesen | |
| VTV THERAPEUTICS | 19,500 | +4,28 % | vTv Therapeutics appoints four new members to scientific advisory board | ||
| QUOIN PHARMACEUTICALS | 21,800 | +221,53 % | Crude Oil Falls Over 4%; Quoin Pharmaceuticals Shares Spike Higher | ||
| NEUPHORIA THERAPEUTICS | 17,630 | -7,74 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates | Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal... ► Artikel lesen | |
| NUVATION BIO | 3,735 | -0,27 % | Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer | Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,120 | +2,75 % | MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction | Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,300 | +3,17 % | JPMorgan downgrades Pliant Therapeutics stock rating to Underweight from Neutral | ||
| ONCONETIX | 3,340 | +9,15 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,155 (-7,35 %) liegt der Kurs bei 1,955 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.